In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).
作者信息
Khan Abbas, Heng Wang, Wang Yanjing, Qiu Jingfei, Wei Xiaoyong, Peng Shaoliang, Saleem Shoaib, Khan Mazhar, Ali Syed Shujait, Wei Dong-Qing
机构信息
Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Peng Cheng Laboratory, Shenzhen, China.
出版信息
Phytother Res. 2021 Jun;35(6):2841-2845. doi: 10.1002/ptr.6998. Epub 2021 Jan 15.
Abstract
摘要
相似文献
1
In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).山奈酚作为严重急性呼吸综合征冠状病毒2主蛋白酶（3CLpro）潜在抑制剂的计算机模拟和体外评估
Phytother Res. 2021 Jun;35(6):2841-2845. doi: 10.1002/ptr.6998. Epub 2021 Jan 15.
2
Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.基于芹菜素的双黄酮衍生物作为潜在治疗 SARS-CoV-2 病毒蛋白酶（3CLpro）的药物的评价：通过分子对接、分子动力学和量子力学研究。
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):5915-5945. doi: 10.1080/07391102.2022.2098821. Epub 2022 Jul 18.
3
Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.采用多维虚拟筛选方法并结合药物重定位，以鉴定新型 SARS-CoV-2 3CL 蛋白酶共价抑制剂。
J Biomol Struct Dyn. 2023;41(24):15262-15285. doi: 10.1080/07391102.2023.2193994. Epub 2023 Mar 24.
4
Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.评估洗必泰和几种类黄酮作为抗 SARS-CoV-2 主蛋白酶的抗病毒药物的效果：分子对接、分子动力学模拟研究。
J Biomol Struct Dyn. 2022 Oct;40(17):7656-7665. doi: 10.1080/07391102.2021.1900919. Epub 2021 Mar 22.
5
Chetomin, a SARS-CoV-2 3C-like Protease (3CL) Inhibitor: Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis.切托明，一种 SARS-CoV-2 3C 样蛋白酶（3CL）抑制剂：筛选、酶对接、分子动力学和药代动力学分析。
Viruses. 2023 Jan 15;15(1):250. doi: 10.3390/v15010250.
6
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.计算机分析与鉴定新型冠状病毒 SARS-CoV-2 的 3-糜蛋白酶样主蛋白酶的抗病毒香豆素衍生物。
Mol Divers. 2022 Apr;26(2):1053-1076. doi: 10.1007/s11030-021-10230-6. Epub 2021 Jul 2.
7
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.基于计算机的 SARS-CoV-2 主要蛋白酶和刺突蛋白药物再利用。
J Proteome Res. 2020 Nov 6;19(11):4637-4648. doi: 10.1021/acs.jproteome.0c00383. Epub 2020 Sep 21.
8
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.羟乙胺类似物的抗病毒评估：针对 SARS-CoV-2 主蛋白酶（3CLpro）的抑制剂，一种虚拟筛选和模拟方法。
Bioorg Med Chem. 2021 Oct 1;47:116393. doi: 10.1016/j.bmc.2021.116393. Epub 2021 Sep 4.
9
Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL).针对 SARS-CoV-2 的药物再利用研究：药物靶点 3C 样蛋白酶（3CL）的综合对接方法。
J Biomol Struct Dyn. 2021 Sep;39(15):5735-5755. doi: 10.1080/07391102.2020.1792344. Epub 2020 Jul 17.
10
Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.天然化合物作为新型冠状病毒主要蛋白酶（3CLpro）的抑制剂：一种对抗新冠肺炎的分子对接和模拟方法
Curr Pharm Des. 2021;27(33):3577-3589. doi: 10.2174/1381612826999201116195851.
引用本文的文献
1
The Omicron variant BA.2.86.1 of SARS- CoV-2 demonstrates an altered interaction network and dynamic features to enhance the interaction with the hACE2.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变种BA.2.86.1表现出改变的相互作用网络和动态特征，以增强与人类血管紧张素转换酶2（hACE2）的相互作用。
Sci Rep. 2025 Feb 22;15(1):6482. doi: 10.1038/s41598-025-89548-2.
2
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关键蛋白的共价抑制剂的结构基础研究进展
Curr Med Chem. 2025;32(19):3790-3824. doi: 10.2174/0109298673323348241208080419.
3
Molecular modeling and simulation approaches to characterize potential molecular targets for burdock inulin to instigate protection against autoimmune diseases.采用分子建模和模拟方法来鉴定牛蒡菊糖潜在的分子靶标，以启动针对自身免疫性疾病的保护作用。
Sci Rep. 2024 May 17;14(1):11291. doi: 10.1038/s41598-024-61387-7.
4
In vitro biological evaluation and in silico insights into the antiviral activity of standardized olive leaves extract against SARS-CoV-2.标准化橄榄叶提取物对SARS-CoV-2抗病毒活性的体外生物学评价和计算机模拟分析
PLoS One. 2024 Apr 25;19(4):e0301086. doi: 10.1371/journal.pone.0301086. eCollection 2024.
5
Exploring NCATS in-house biomedical data for evidence-based drug repurposing.探索美国国立转化医学推进中心（NCATS）内部生物医学数据以进行循证药物重新利用。
PLoS One. 2024 Jan 25;19(1):e0289518. doi: 10.1371/journal.pone.0289518. eCollection 2024.
6
Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins.基于结构的严重急性呼吸综合征冠状病毒2及其德尔塔和奥密克戎变异株蛋白天然抑制剂的虚拟鉴定
Future Virol. 2023 May;18(7):421-438. doi: 10.2217/fvl-2022-0184. Epub 2023 Jun 1.
7
Neuroprotective Agents with Therapeutic Potential for COVID-19.具有治疗潜力的 COVID-19 神经保护剂。
Biomolecules. 2023 Oct 27;13(11):1585. doi: 10.3390/biom13111585.
8
WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.WGX50 通过抑制线粒体 ROS 和铁死亡减轻阿霉素诱导的心脏毒性。
J Transl Med. 2023 Nov 17;21(1):823. doi: 10.1186/s12967-023-04715-1.
9
Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein.探索天然产物和抗高血压药物对 SARS-CoV-2 的结合作用：对主蛋白酶和刺突蛋白的计算机模拟研究。
Int J Mol Sci. 2023 Nov 2;24(21):15894. doi: 10.3390/ijms242115894.
10
Exploring the medicinal potential of Dark Chemical Matters (DCM) to design promising inhibitors for PLpro of SARS-CoV-2 using molecular screening and simulation approaches.利用分子筛选和模拟方法探索暗化学物质（DCM）的药用潜力，以设计出有前景的针对新冠病毒木瓜蛋白酶样蛋白酶（PLpro）的抑制剂。
Saudi Pharm J. 2023 Oct;31(10):101775. doi: 10.1016/j.jsps.2023.101775. Epub 2023 Aug 30.
本文引用的文献
1
Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).联合药物重定位和虚拟筛选策略与分子动力学模拟鉴定出针对 SARS-CoV-2 主要蛋白酶（3CLpro）的有效抑制剂。
J Biomol Struct Dyn. 2021 Aug;39(13):4659-4670. doi: 10.1080/07391102.2020.1779128. Epub 2020 Jun 18.
2
Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7).基于片段分子轨道的 COVID-19 主蛋白酶-抑制剂 N3 复合物（PDB ID：6LU7）相互作用分析。
J Chem Inf Model. 2020 Jul 27;60(7):3593-3602. doi: 10.1021/acs.jcim.0c00283. Epub 2020 Jun 25.
3
Repurposing cefuroxime for treatment of COVID-19: a scoping review of studies.重新利用头孢呋辛治疗 COVID-19：研究的范围综述。
J Biomol Struct Dyn. 2021 Aug;39(12):4547-4554. doi: 10.1080/07391102.2020.1777904. Epub 2020 Jun 13.
4
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.柳参胶囊通过抑制 NF-κB 信号通路显示出对新型冠状病毒 SARS-CoV-2 的抗病毒和抗炎能力。
Pharmacol Res. 2020 Aug;158:104850. doi: 10.1016/j.phrs.2020.104850. Epub 2020 Apr 30.
5
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.基于结构的针对 SARS-CoV-2 主蛋白酶的抗病毒药物候选物的设计。
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
6
A new coronavirus associated with human respiratory disease in China.一种在中国与人类呼吸道疾病相关的新型冠状病毒。
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Inhibition of SARS-CoV 3CL protease by flavonoids.黄酮类化合物对 SARS-CoV 3CL 蛋白酶的抑制作用。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-151. doi: 10.1080/14756366.2019.1690480.
Zotero 插件